

is May 5, 1995. Please note that this is a departure from the traditional approach of using postmarks instead of receipt date to determine eligibility of applications for review.

ADDRESSES: Application receipt: Department of Health and Human Services, ACF Division of Discretionary Grants, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447. Attn: ACF-93588.951-A.

FOR FURTHER INFORMATION ON THE COMMUNITY SCHOOLS PROGRAM CONTACT: Department of Health and Human Services, AC/ACYF, Family and Youth Services Bureau, P.O. Box 1182, Washington, D.C. 20013. Telephone (202) 205-8076. Information is also available on the ACF Electronic Bulletin Board. To access, set modem to No Parity, 8 Data Bits, 1 Stop Bit and dial 1-800-627-8886. Under "Program Office Subsystems, Family and Youth Services Bureau," relevant files are found under COMMSCH.

FOR FURTHER INFORMATION ON THE FACES PROGRAM CONTACT: Department of Education, OESE, Safe and Drug Free Schools Program, 600 Independence Avenue, S.W., Washington, D.C. 20202. Telephone (202) 260-3954.

Catalog of Federal Domestic Assistance Number 84.285A for the FACES Program and Number 93.588 for the Community School Program.)

Dated: March 7, 1995.

Olivia A. Golden,

Commissioner, Administration on Children, Youth and Families.

[FR Doc. 95-6252 Filed 3-13-95; 8:45 am]

BILLING CODE 4184-01-P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreements for National/Regional Minority Organization Human Immunodeficiency Virus (HIV)/Sexually Transmitted Diseases (STD) Prevention, Immunization, and Tuberculosis (TB) Projects-Program Announcement 305b: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for National/Regional Minority Organization HIV/STD Prevention, Immunization, and TB Projects-Program Announcement 305b.

Time and Date: 8:30 a.m.-4:30 p.m., April 18, 1995.

Place: Corporate Square, Building 11, Room 2320, Corporate Square Boulevard, Atlanta, Georgia 30329.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 305b. The applications being reviewed include information of a confidential nature, including personal information concerning individuals associated with the applications.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Contact Person for More Information: John R. Lehnerr, Chief, Resource Analysis Office (E07), National Center for Prevention Services, CDC, Corporate Square, Corporate Square Boulevard, Atlanta, Georgia 30329, telephone 404/639-8023.

Dated: March 7, 1995.

Arthur C. Jackson,

Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-6236 Filed 3-13-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

Comparing Treatments: Safety, Effectiveness, and Cost-Effectiveness; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it is holding a meeting to explore methodological and regulatory issues in the design and review of studies intended to show differences or similarities among active drug and biological therapies. As the pharmaceutical marketplace evolves, there are new pressures on the developers of drug/biological products to demonstrate comparative effects. This meeting will examine the needs for this type of information, how the pharmaceutical industry is responding to new demands for comparative information, case-study experience ruling out biases in study design, the use of observational studies, methodological concerns in effectiveness trials, and promotional considerations. The study will examine issues concerning evaluation of safety, effectiveness, and cost-effectiveness.

DATES: The meeting will be held on Thursday, March 23, 1995, 8 a.m. to

5:30 p.m., and on Friday, March 24, 1995, 8:30 a.m. to 5 p.m.

ADDRESSES: The meeting will be held at the National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. Copies of the transcript of the meeting will be available from the contact person listed below. There is no registration fee for this meeting. Interested persons are encouraged to register early because space is limited.

FOR FURTHER INFORMATION CONTACT: Regarding information concerning the meeting and registration forms: Louis A. Morris, Center for Drug Evaluation and Research (HFD-240), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-6812, FAX 301-594-6759.

Dated: March 8, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-6199 Filed 3-13-95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Rural Regional Trauma and Emergency Medical Services System Demonstration Grant Project in South Central Florida

AGENCY: Health Resources and Services Administration, Public Health Service, Department of Health and Human Services.

ACTION: Notice of extension of application due date.

SUMMARY: This notice extends the application due date for a Rural Regional Trauma and Emergency Medical Services (EMS) Demonstration Grant Project in South Central Florida. The application due date for the South Central Florida project is extended to May 15, 1995. All other aspects of the February 15, 1995 Federal Register Notice remain the same.

Dated: March 9, 1995.

Ciro V. Sumaya,

Administrator.

[FR Doc. 95-6198 Filed 3-13-95; 8:45 am]

BILLING CODE 4160-15-M

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Committee Name: National Institute of General Medical Sciences, Special Emphasis Panel—Minority Biomedical Research Support and Undergraduate Program Expertise.

Date: March 28.

Time: 1 p.m.—adjournment.

Place: Holiday Inn, 348 N. Dupont Highway, Dover, DE 19901.

Contact Person: Dr. Bruce Wetzel, Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS-19K, Bethesda, MD 20892-6200.

Purpose: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS].

Dated: March 8, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-6186 Filed 3-13-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Chronic Fatigue Syndrome Interagency Coordinating Committee; Public Meeting

Notice is hereby given of the public meeting of the Chronic Fatigue Syndrome (CFS) Interagency Coordinating Committee, Department of Health and Human Services, on April 12, 1995 at the Hubert H. Humphrey Building, Room 729G, 200 Independence Avenue, SW, Washington, DC.

The meeting will be open to the public from noon to 3 p.m., on April 12, to discuss the current CFS activities and future plans of the various member agencies. It will be chaired by the Assistant Secretary for Health. During the meeting there will be an opportunity for interested persons to present information and views on issues related to CFS. Attendance by the public will be limited only by space available.

If you plan to attend the meeting, please provide your name, organization, address, telephone and FAX numbers to Dr. John La Montagne, Co-Chair, Chronic Fatigue Syndrome Interagency Coordinating Committee, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Solar Building, Room 3A18 MSC 7630, Bethesda, MD 20892-7630. Telephone: 301-496-1884, FAX: 301-480-4528. If you also plan to make a presentation, please notify Dr. La Montagne. The time available will be allocated among the individuals who request an opportunity for a presentation (limited to five minutes). Formal written statements (five copies) may be presented to the Chair on the day of the meeting for inclusion in the minutes.

Dated: March 2, 1995.

Anthony S. Fauci,

Director, NIAID, NIH.

[FR Doc. 95-6188 Filed 3-13-95; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda

To review Small Business Innovation Research Program grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: April 14, 1995.

Time: 9 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. A. Keith Murray, Scientific Review Admin., 5333 Westbard Ave., Room 325, Bethesda, MD 20892, (301) 594-7145.

Purpose/Agenda

To review individual grant applications

Name of SEP: Microbiological and Immunological Sciences.

Date: March 23, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 406B, Telephone Conference.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave., Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 27, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 406B, Telephone Conference.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave.,

Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 28, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 406B, Telephone Conference.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave., Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 29, 1995.

Time: 1 p.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave., Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 30, 1995.

Time: 1:30 p.m.

Place: NIH, Westwood Building, Room 406B, Telephone Conference.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave., Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 31, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 406B, Telephone Conference.

Contact Person: Dr. Gil Meier, Scientific Review Administrator, 5333 Westbard Ave., Room 406B, Bethesda, MD 20892, (301) 594-7118.

Name of SEP: Multidisciplinary Sciences.

Date: April 3, 1995.

Time: 9 a.m.

Place: NIH, Westwood Building, Room 437, Telephone Conference.

Contact Person: Dr. Paul Parakkal, Scientific Review Admin., 5333 Westbard Ave., Room 437, Bethesda, MD 20892, (301) 594-7258.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893. National Institutes of Health, HHS)